Publications | Lund University Publications

11 – 20 of 41

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/publication?embed=1&q=issn+exact+%220923-7534%22&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2019
Mark Vitamin B6 catabolism and lung cancer risk : Results from the Lung Cancer Cohort Consortium (LC3)
Zuo, H. ; Ueland, P. M. ; Midttun ; Tell, G. S. ; Fanidi, A. ; Zheng, W. ; Shu, X. ; Xiang, Y. ; Wu, J. ^LU and Prentice, R. , et al. (2019) In Annals of Oncology 30(3). p.478-485
- Contribution to journal › Article
Mark Early breast cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F. ; Kyriakides, S. ; Ohno, S. ; Penault-Llorca, F. ; Poortmans, P. ; Rubio, I. T. ; Zackrisson, S. ^LU and Senkus, E. (2019) In Annals of Oncology 30(8). p.1194-1220
- Contribution to journal › Article
Mark Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden : A SCAN-LEAF study analysis from the I-O Optimise initiative
Sørensen, J. B. ; Ekman, S. ; Brustugun, O. T. ; Horvat, P. ; Patel, D. ; Rosenlund, M. ; Mette Kejs, A. ; Juarez-Garcia, A. ; Daumont, M. and Lacoin, L. , et al. (2019) In Annals of Oncology 30(Suppl 2). p.16-17
- Contribution to journal › Published meeting abstract
Mark Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden : A SCAN-LEAF study analysis from the I-O Optimise initiative
Ekman, S. ; Sørensen, J. B. ; Brustugun, O. T. ; Horvat, P. ; Patel, D. ; Rosenlund, M. ; Mette Kejs, A. ; Juarez-Garcia, A. ; Daumont, M. and Lacoin, L. , et al. (2019) In Annals of Oncology 30(Suppl 2). p.17-17
- Contribution to journal › Published meeting abstract
2018
Mark Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
Friedlander, Michael ; Rau, J. ; Lee, C. K. ; Meier, W. ; Lesoin, A. ; Kim, J. W. ; Poveda, A. ; Buck, M. ; Scambia, G. and Shimada, M. , et al. (2018) In Annals of Oncology 29(3). p.737-743
- Contribution to journal › Article
Mark Bone sarcomas : ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Casali, P. G. ; Bielack, S. ; Abecassis, N. ; Aro, H. T. ; Bauer, S. ; Biagini, R. ; Bonvalot, S. ; Boukovinas, I. ; Bovee, J. V.M.G. and Brennan, B. , et al. (2018) In Annals of Oncology 29. p.79-95
- Contribution to journal › Article
Mark Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma
Kwong, Y. L. ; Kim, S. J. ; Tse, E. ; Oh, S. Y. ; Kwak, J. Y. ; Eom, H. S. ; Do, Y. R. ; Mun, Y. C. ; Lee, S. R. and Shin, H. J. , et al. (2018) In Annals of Oncology 29(1). p.256-263
- Contribution to journal › Article
Mark The genomic grade index predicts postoperative clinical outcome in patients with soft-tissue sarcoma
Bertucci, F. ; De Nonneville, A. ; Finetti, P. ; Perrot, D. ; Nilbert, M. ^LU ; Italiano, A. ; Le Cesne, A. ; Skubitz, K. M. ; Blay, J. Y. and Birnbaum, D. (2018) In Annals of Oncology 29(2). p.459-465
- Contribution to journal › Article
Mark Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer : The RASTEN trial
Ek, L. ^LU ; Gezelius, E. ^LU ; Bergman, B. ; Bendahl, P. O. ^LU ; Anderson, H. ^LU ; Sundberg, J. ; Wallberg, M. ^LU ; Falkmer, U. ; Verma, S. and Belting, M. ^LU (2018) In Annals of Oncology 29(2). p.398-404
- Contribution to journal › Article
Mark Anti-angiogenic action of leukotriene-C4 induced 15-hydroxyprostaglandin dehydrogenase in colon cancer cells is a TNF-α dependent phenomenon
Satapathy, S. ^LU and Sjolander, A. ^LU (2018) In Annals of Oncology 29(Suppl. 5). p.55-55
- Contribution to journal › Article

your query:: Remove issn: 0923-7534